Overview
Information & Communication

ADR120S,Inc.

ADR120S Group develops cell therapies using Adipose Derived Regenerative Cells (ADRCs) extracted from patients' own subcutaneous fat tissue via its proprietary Celution device system. The technology enables same-day autologous cell therapy without the need for cell cultivation, avoiding rejection reactions and immunosuppressants. The group also engages in medical asset investment, real estate sales and management through its subsidiaries.

Market Cap
¥6.68B
US$42.6M
EV
¥6.85B
US$43.7M
Stock¥748▼-0.80%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
NM
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
NM
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-32.5%pt
100
Oct 24, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
6.68BUS$42.6MMarket Cap0.25BUS$1.59M+ Debt0.07BUS$0.43M− Cash0.01BUS$0.07M− Inv. Sec.6.85BUS$43.7MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
1.34US$8.51M'22/32.14US$13.7M'23/31.56US$9.95M'24/30.12US$0.78M'25/30.05US$0.32M'26/3
EBITDA 5Y (¥B)
-0.19-US$1.19M'22/3-0.51-US$3.24M'23/3-0.56-US$3.59M'24/3-0.76-US$4.82M'25/3-0.91-US$5.77M'26/3
Net Income 5Y (¥B)
-0.08-US$0.49M'22/3-1.06-US$6.75M'23/30.14US$0.88M'24/3-2.14-US$13.6M'25/3-0.40-US$2.53M'26/3
Capital Structure
140%
EquityDebt
Liquidity vs Debt 5Y (¥B)▼ Net Debt
CashInv. Sec.Debt
0.85US$5.43M9.27US$59.1M'22/31.12US$7.16M8.51US$54.3M'23/31.04US$6.62M2.47US$15.8M'24/30.26US$1.63M2.65US$16.9M'25/30.14US$0.87M'26/3
Shareholders
Top 10 hold 75.5%
1
HG Capital Co., Ltd.
12.92%
2
SBI SECURITIES Co., Ltd.
12.03%
3
Masamichi HASHIMOTO
11.85%
4
FTL Capital Management Co., Ltd.
11.05%
5
Tokyo Weld Co., Ltd.
9.22%
6
Japan Securities Finance Co.,Ltd.
6.65%
7
Satoyasu HORIE
5.16%
8
Yoshiro KUBOTA
4.21%
9
Rikiichi SUGIYAMA
1.27%
10
Keisuke KUBOTA
1.15%
Management
8 officers
Masamichi HASHIMOTO
Chairman and Representative Director
Dec 2016 Director, HG Capital Co., Ltd. Jul 2017 Representative Director, HG Holdings Co., Ltd. (current) Oct 2018 Representative Director, HG Capital Co., Ltd. (current) Jul 2019 Representative Director, 3H Racing Co., Ltd. (current) Feb 2025 Director, the Company Jun 2025 Representative Director, ADR Therapeutics Co., Ltd. (current) Jun 2025 Representative Director and President, the Company Jun 2026 Chairman and Representative Director, the Company (current)
1969-08-31
Ryuji SUZUKI
Representative Director, President
Apr 2013 Assistant Professor, Pancreatic Surgery, Digestive Disease Center Surgery, Tokyo Women's Medical University Apr 2015 Chief, Department of Surgery, Tsukuba Gastroenterology Hospital Jun 2020 Chairman, Medical Corporation Chikusankai Tsukuba Gastroenterology Hospital (current) Jun 2026 Representative Director, President, the Company (current)
1980-08-31
Naoyuki INOUE
Director
Apr 1977 Joined Toyota Motor Sales, Co., Ltd. (now Toyota Motor Corporation) Apr 2011 General Manager, Oceania Department, Toyota Motor Corporation General Manager, Overseas Planning Department, Toyota Motor Corporation General Manager, Global Sales Planning Division, Toyota Motor Corporation Managing Officer, Toyota Motor Corporation General Manager, Central Asia and Middle East Division, Toyota Motor Corporation Apr 2012 Senior Managing Officer, Toyota Motor Corporation Apr 2013 General Manager, Asia and Middle East Division, Toyota Motor Corporation Apr 2013 President and Representative Director, Toyota Motor Asia Pacific Engineering and Manufacturing Co., Ltd. Apr 2013 President and Director, Toyota Motor Asia Pacific Pte. Ltd. (Singapore) Apr 2013 Audit & Supervisory Board Member, Astra International Co., Ltd. Jun 2015 President and Director, Tokyo Toyota Motor Corporation Feb 2025 Director, the Company (current)
1953-10-31
Masaru AMAGASA
Director
Aug 1996 Joined Ochanomizu General Accounting Office Apr 1999 Joined Merrill Lynch Japan Securities Co., Ltd. Feb 2001 Registered as Certified Tax Accountant; opened Chiyoda Tax Accountant Office, Head (current) Jun 2006 Director, METS Co., Ltd. Feb 2007 Audit & Supervisory Board Member, METS Co., Ltd. Dec 2007 Representative Director, Chiyoda Consulting Co., Ltd. (current) Jun 2019 Representative Director, Work System Design Co., Ltd. (current) Jun 2025 Director, the Company (current)
1972-06-19
Hisato HAYASHI
Director
Apr 2006 Joined Nissan Chemical Industries, Ltd. (now Nissan Chemical Corporation) Jul 2009 Assistant Senior Researcher, New Materials Group, Synthesis Research Department, Materials Science Research Laboratory, Nissan Chemical Corporation Jul 2015 Senior Researcher, Next-Generation Materials Research Department, Materials Science Research Laboratory, Nissan Chemical Corporation Oct 2016 Senior Staff, New Business Planning Department, Head Office, Nissan Chemical Corporation Apr 2021 Senior Staff, Healthcare Planning Department, Planning Division, Head Office, Nissan Chemical Corporation Jan 2025 Joined Cytori Therapeutics Co., Ltd. (now ADR Therapeutics Co., Ltd.), Assistant to the President Jan 2025 Executive Officer, Business Management, Cytori Therapeutics Co., Ltd. Mar 2025 Representative Director, President, ADR Therapeutics Co., Ltd. (current) Jun 2025 Director, the Company (current)
1977-12-04
Hiroki KOBAYASHI
Director (Audit and Supervisory Committee Member)
Apr 1992 Joined Sumitomo Bank, Ltd. (now Sumitomo Mitsui Banking Corporation) Jun 1998 Financial Crime Investigator, Osaka Prefectural Police Headquarters Jul 2008 Joined FIT Co., Ltd. Dec 2009 Director, FIT Co., Ltd. Aug 2011 Established Accurate Advisors Co., Ltd.; Representative Director (current) Jun 2012 Outside Audit & Supervisory Board Member, B-Map Co., Ltd. (current) Sep 2023 Audit & Supervisory Board Member, ADR Therapeutics Co., Ltd. (formerly Cytori Therapeutics Co., Ltd.) (current) Oct 2023 Director (Audit and Supervisory Committee Member), the Company (current)
1969-11-24
Hidehiko HISAOKA
Director (Audit and Supervisory Committee Member)
Nov 1980 Joined Department of Anesthesiology, Juntendo University Hospital Jun 1984 Joined Department of Cardiology, Juntendo University Hospital Feb 1996 Received Doctor of Medical Science, Juntendo University Aug 2003 Director, Emergency Room, Juntendo University Hospital Jun 2005 Associate Professor, Department of General Medicine, Juntendo University Hospital Jun 2007 Director, Juntendo Medical Insurance Office Jun 2013 Professor, Department of General Medicine, Juntendo University Hospital Apr 2018 Specially Appointed Professor, Juntendo University School of Medicine and Graduate School of Medicine (current) Feb 2024 Director (Audit and Supervisory Committee Member), the Company (current)
1952-09-26
Hiroaki KOBAYASHI
Director (Audit and Supervisory Committee Member)
Oct 1989 Passed National Bar Examination Mar 1992 Completed Legal Training and Research Institute (44th Class) Apr 1992 Registered as Attorney; joined Sakaguchi Law Office Apr 1998 Established Legal Plaza Law Office Jan 2003 Established B. Positive Law Office; Representative (current) Jun 2025 Director (Audit and Supervisory Committee Member), the Company (current)
1960-08-22
Large Shareholding Reports
Tokyo Wells Co., Ltd.
2026-05-08
9.22%→9.22%
Annual report (as of 2026-03-31): 9.22%
FTL Capital Management Co., Ltd.
2025-10-22
11.05%
Annual report (as of 2026-03-31): 11.05%
Disclosures
No disclosures
Primary Source Filings
TDnet
2026-08-14
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-26
Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2026-05-08
Large Shareholding Report
TDnet
2026-02-13
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-11-14
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINETAmended
2025-11-07
Amended Annual Securities Report
Period: Apr 2024 – Mar 2025
EDINET
2025-10-22
Large Shareholding Report
TDnet
2025-08-14
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-27
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-14
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-14
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-14
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-26
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-09
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINETAmended
2023-08-30
Amended Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINETAmended
2023-07-11
Amended Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-06-23
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-10
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-11
Quarterly Securities Report
EDINET
2022-08-10
Quarterly Securities Report
EDINET
2022-06-23
Annual Securities Report
EDINET
2022-02-10
Quarterly Securities Report
EDINET
2021-11-10
Quarterly Securities Report
EDINET
2021-08-11
Quarterly Securities Report
EDINET
2021-06-24
Annual Securities Report
EDINET
2021-02-10
Quarterly Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →